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The N-myristoylome of 
Trypanosoma cruzi
Adam J. Roberts & Alan H. Fairlamb
Protein N-myristoylation is catalysed by N-myristoyltransferase (NMT), an essential and druggable target 
in Trypanosoma cruzi, the causative agent of Chagas’ disease. Here we have employed whole cell labelling 
with azidomyristic acid and click chemistry to identify N-myristoylated proteins in different life cycle 
stages of the parasite. Only minor differences in fluorescent-labelling were observed between the dividing 
forms (the insect epimastigote and mammalian amastigote stages) and the non-dividing trypomastigote 
stage. Using a combination of label-free and stable isotope labelling of cells in culture (SILAC) based 
proteomic strategies in the presence and absence of the NMT inhibitor DDD85646, we identified 56 
proteins enriched in at least two out of the three experimental approaches. Of these, 6 were likely to be 
false positives, with the remaining 50 commencing with amino acids MG at the N-terminus in one or more 
of the T. cruzi genomes. Most of these are proteins of unknown function (32), with the remainder (18) 
implicated in a diverse range of critical cellular and metabolic functions such as intracellular transport, cell 
signalling and protein turnover. In summary, we have established that 0.43–0.46% of the proteome is  
N-myristoylated in T. cruzi approaching that of other eukaryotic organisms (0.5–1.7%).
The protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, which continues to be a major 
health concern in Latin American countries where these parasites are endemic. It is estimated there are ~8 mil-
lion infected individuals worldwide with over 10,000 deaths annually, mainly due to cardiac disease arising as a 
consequence of the immune response to the chronic infection1–3. Current treatment options are limited to two 
nitroheterocyclic drugs, benznidazole and nifurtimox, with limited efficacy and toxicity4,5. Better, safer drugs are 
needed, but recent clinical trials with ergosterol biosynthesis inhibitors have been disappointing6,7.
The lifecycle of this parasite consists of three morphologically distinct developmental stages, the epimastigote, 
trypomastigote and the amastigote (see review8). Epimastigotes are the non-infective stage found only in the 
hind-gut of triatomine bugs. These insects are the primary source of parasite transmission and human infection9, 
although other routes such as blood transfusion, organ transplantation, ingestion of food or drink or vertical 
transmission are known8. Trypomastigotes are the infective and non-dividing stage either found in the faeces of 
the insect vector or circulating in the bloodstream of a mammalian host. Amastigotes are the replicative forms 
found intracellularly in a wide range of mammalian cells throughout the body, but can also be detected circulating 
in the blood10,11.
The acylation of proteins with fatty acids of various chain lengths occurs in all domains of life (see review12). 
The resulting effect of these modifications can range from regulating biological activity to controlling the subcel-
lular localisation of a protein13–15. In particular, myristic acid, which accounts for ~1.5% of the total lipid content 
of these parasites16 can be attached to proteins via a cysteine residue (S-myristoylation)17 or the N-terminal glycine 
of specific proteins (N-myristoylation)18,19. This latter process is catalysed by the enzyme N-myristoyltransferase 
(NMT; E.C. number 2.3.1.97), which utilizes myristoyl-CoA as an acyl donor and is present in all eukaryotes19. 
Bioinformatic studies have suggested that ~0.5–1.7% of a eukaryotic proteome may be myristoylated20,21. 
Although this a conserved biological process, multiple studies have found species-specific differences in the pep-
tide substrates recognised by each NMT homologue, with a greater divergence observed between higher and 
lower eukaryotes22–24. These subtle differences have been exploited to generate species-selective NMT inhibitors 
for the Candida albicans25,26, Leishmania spp27,28, Trypanosoma brucei29,30 and Plasmodium falciparum homologs28.
Previous work from our lab has demonstrated that NMT is both a druggable and essential target in T. cruzi31, 
similar to the related parasites T. brucei30 and L. major27,32. The specific inhibition of N-myristoylation in T. cruzi 
using the potent NMT inhibitor DDD8564630, consequentially led to a reduction in parasite proliferation in the 
epimastigote stage31. In order to ascertain if N-myristoylated proteins themselves may be potential therapeu-
tic targets in T. cruzi, the N-myristoylome first needs to be identified and characterised. This study has sought 
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to overcome the uncertainty associated with identifying N-myristoylation by bioinformatics alone using a 
bead-based chemical proteomic strategy. This approach has led to the robust identification of 50 proteins involved 
in a variety of cellular pathways and functions.
Results
T. cruzi N-myristoylation. Previous work from our lab has identified that NMT is continuously expressed 
throughout the lifecycle of the parasite31. To determine the relative expression of N-myristoylated proteins in all 
life-cycle stages, the incorporation of the myristic acid analogue, azidomyristate, was monitored using click chem-
istry and SDS-PAGE as a measure of N-myristoylation. In all samples labelled with or without azidomyristate, 
the fluorescent dye was found to cross-react with a non-specific band at ~50 kDa. Azidomyristate was incorpo-
rated into at least 10 bands visible in SDS-PAGE gels in epimastigotes, trypomastigotes and amastigotes (Fig. 1a). 
These bands were insensitive to base treatment suggesting that they had been incorporated via an N-terminal 
amide bond, rather than by S-myristoylation17. Analysis by densitometry revealed at least 18 bands common to all 
stages, some of which varied in intensity between the lifecycle stages (Fig. 1b) despite an equal amount of protein 
loaded as assessed by Coomassie blue staining (Fig. 1c). Thus, our results demonstrate that there are only minor 
stage-specific variations in the labelling of the most abundant N-myristoylated proteins.
N-myristoylation is co- rather than post-translational. This modification has been reported to occur 
post-translationally during apoptosis in mammalian cells, where proteolytic cleavage reveals a hidden myristoy-
lation motif 33,34. To elucidate if this can occur post-translationally in T. cruzi, incorporation of azidomyristate 
was assessed in epimastigotes where nascent protein synthesis was inhibited by pre-treatment with cyclohex-
imide. Examination by microscopy and Live/Dead assay revealed cycloheximide treatment had no effect on the 
viability of the cells. N-myristoylation in the epimastigote was greatly reduced or abolished to below the limits 
of detection in the presence of cycloheximide for the majority of bands (Fig. 2a). However, two out of the three 
most prominent azidomyristoylated bands at 24 and 16 kDa were partially resistant to cycloheximide treatment 
in epimastigotes. To assess if this was a failure to inhibit nascent protein synthesis, concurrent labelling with 
L-[35S]-methionine was undertaken (Fig. 2b). This revealed no detectable protein synthesis in parasites that had 
been treated with cycloheximide possibly suggesting that these bands may be the result of post-translational 
myristoylation.
The identification of N-azidomyristoylated proteins. To identify the proteins undergoing this modi-
fication, we directly captured and enriched N-azidomyristoylated proteins using bead-based click-chemistry and 
on-resin trypsin digestion followed by analysis by mass spectrometry (Fig. 3). Epimastigotes labelled with azido-
myristate grew at the same rate as the control for the first 27 h, after which the presence of this analogue was det-
rimental to parasite growth (Fig. 4a). Epimastigotes have a doubling time of approximately18–22 h, so a labelling 
period of 20 h was selected for label-free quantitation as this would maximise labelling of cell cycle-dependent pro-
teins and proteins with a slow turnover, whilst avoiding cell toxicity. Enrichments were made from urea-solubilised 
whole cell lysates of control or azidomyristate-labelled parasites carried out from three independent biological 
replicates. Stringent washing and hydroxylamine treatment of the resin was carried out to remove S-myristoylated 
proteins, non-specific binding proteins and missing label-free quantitation (LFQ) values, imputed from a normal 
distribution. Significance was assessed using a permutation based t-test, identifying 56 proteins to be significantly 
(t-test, 250 permutations, S0 = 2, FDR q < 0.05) enriched over the controls (Fig. 4b orange and blue). Removal of 
Figure 1. Comparative N-myristoylation throughout the T. cruzi life cycle. (a) The incorporation of azidomyristate 
(AzMyr) into the epimastigote (Epi), trypomastigote (Trypo) and amastigote (Ama) proteomes was visualised 
using click chemistry. (b) Fluorescence intensity profile of the epimastigote (red), trypomastigote (blue), 
amastigote (black) N-myristoylated proteins, assessed by in-gel fluorescence. (c) Coomassie blue stained gel.
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the imputed values showed that the majority of enriched proteins had not been identified in any control exper-
iment (Fig. 4b, orange), with 8 out of 56 having been identified in at least one control (Fig. 4b, blue). Of the 56 
enriched proteins identified 79% were predicted to have an N-terminal methionine followed by a glycine residue 
(Table S2). Overall, this represents a 15-fold enrichment over the database average of 5.26% of proteins commenc-
ing with MG, as would be expected for the enrichment of N-myristoylated proteins from this parasite.
To minimise sample handling and processing errors, we opted to perform a further 2 experiments using stable 
isotope labelling of cells in culture (SILAC) to determine if there were N-azidomyristoylated proteins that also 
Figure 2. Co- versus post-translational N-myristoylation. Epimastigotes were pre-incubated in the 
presence and absence of cycloheximide (CHX) prior to labelling with azidomyristate (AzMyr) and subsequent 
visualisation by in-gel fluorescence (a). L-[35S]-methionine incorporation was measured by autoradiography 
(b). Coomassie blue stained gel showing equal loading (c).
Figure 3. Enrichment strategy for the identification of the T. cruzi N-myristoylome (a) N-azidomyristoylated 
proteins were directly captured onto an alkyne-agarose resin using click chemistry. Stringent washing of the 
resin under denaturing conditions is designed to remove non-specific contaminants. Enriched proteins were 
digested on resin with trypsin and the recovered peptides were analysed by LC-MS/MS.
www.nature.com/scientificreports/
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bound non-specifically to beads. As the culture medium RTH/FCS is undefined (contains trypticase peptone), 
the more chemically defined medium SDM-79 was used for isotopic labelling as it has been reported to support 
the growth of epimastigotes35 and has been successfully used for SILAC studies in T. brucei36. The parasites were 
found to grow at similar rates in both the heavy and light media (Fig. 5a). Enrichments were made from the 
isotopically-labelled parasites with the labels swapped for the second enrichment. The data was adjusted to the 
mode value for both enrichments (Fig. S1). Significance A and B tests only identified a single protein with sta-
tistical significance, possibly due to the non-normal distribution of log2 H/L ratios. Under the assumption that 
the majority of protein ratios would remain unchanged, arbitrary cut-off values for enrichment of < 1 and > 1 
for experiments 1 and 2 respectively were assigned (Fig. S1). Overall, 77 proteins were identified in both SILAC 
biological replicates (Fig. 5b and Table S2), 58% of which were annotated to have a glycine at position 2.
As a result of the direct capture-enrichment approach, the N-terminal azidomyristoylated-peptide is retained 
on the agarose, so a secondary digestion of both SILAC samples with polymyxin acylase was carried out with 
the aim of releasing these peptides37. Although peptides were recovered from replicates 1 and 2 (2 and 4 pep-
tides, respectively, see Table S3), these did not possess an N-terminal glycine residue. Only one of these peptides 
matched a protein enriched in one of the replicates, (K4EBF6, 846 amino acids). A BLAST search of this protein 
against the CL-Brener genome identified a hypothetical gene (TcCLB.509213.40) encoding a protein of 748 res-
idues commencing with MG. This contained a motif (pfam08432: Vfa1), postulated to be involved in regulating 
the trafficking of other proteins to the endocytic vacuole. However, alignment of the orthologues from Silvio and 
Dm28c with CL-Brener strains revealed markedly different N-terminal sequences with MG only in the latter 
strain, despite near identity over the 720 amino acids towards the C-terminus. Similar BLAST searches with the 
Figure 4. Proteomic analysis of the T. cruzi N-myristoylome. (a) Growth of T. cruzi epimastigotes in RTH/
FCS supplemented with DMSO (open circles) or azidomyristate (closed circles). (b) Volcano plot displaying 
the enrichment of N-myristoylated proteins from three independent biological replicates. The line shows the 
significance threshold for the t-test with permutation-based FDR (q < 0.05), with significantly enriched proteins 
absent from all controls (orange), significantly enriched proteins identified in at least one control (blue) and 
non-significant (black).
Figure 5. SILAC studies of N-azidomyristoylation in T. cruzi epimastigotes. (a) Epimastigotes were grown 
in SDM-79 medium supplemented with light (open circles) or heavy (closed circles) isotopically labelled amino 
acids. (b) Log2 H/L ratios plotted for SILAC experiments 1 (x axis) and 2 (y axis).
www.nature.com/scientificreports/
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other 5 peptides did not reveal any genes encoding proteins with an upstream MG start site. Most likely, their 
identification is probably a result of carryover from the initial experiments, despite extensive washing of the resin. 
This suggests that polymyxin acylase is not capable of de-acylating, click-immobilised acyl peptides, possibly due 
to steric hindrance. Further experiments are required to substantiate this hypothesis.
Analysis of enriched proteins. By combining both the label-free and SILAC data, we found 48 consist-
ently enriched proteins of which > 80% were annotated to have an N-terminal MG (Table S2). Those proteins 
with a predicted function or suspected misannotation are listed in Table 1. Some of these have previously been 
reported to be N-myristoylated in other organisms, including CAP5.5 that has been previously identified in 
T. cruzi31. However, two proteins that have been reported to be N-myristoylated in T. cruzi were not enriched in 
all experiments. The flagellar calcium binding protein (FCaBP)38 was significantly enriched (t-test, 250 permuta-
tions, S0 = 2, FDR q < 0.001) in the label free studies and identified, but not quantified in the SILAC experiments. 
In the case of the phosphoinositide phospholipase C39, this was identified in only 2 out of 5 experiments. One 
of the consistently enriched sequences was annotated without an N-terminal methionine in the X10/1 genome, 
therefore proteins without an annotated N-terminal MG were searched using BLAST to determine the likelihood 
of correct annotation. This revealed that 3 out of the 9 non-MG proteins may have been incorrectly curated in the 
X10/1 proteome, because sequences from other T. cruzi genome strains had alternative initiation of translation 
sites commencing with MG downstream of the X10/1 sequences (Fig. 6a–c). This observation is supported by the 
fact that no peptides were identified upstream of the potential downstream MG sites for any of these potentially 
misannotated proteins.
Profiling the enrichment of myristoylated proteins in the presence of an NMT inhibitor. 
The NMT inhibitor DDD85646 has previously been shown to inhibit N-myristoylation in T. cruzi and 
other parasites by both gel-based and label-free proteomic approaches31,40,41. Thus, we attempted to con-
firm the incorrect-annotation of the enriched proteins lacking an apparent N-terminal MG by incubating 
light, medium and heavy labelled parasites with azidomyristate in the absence and presence of DDD85646 
(0–50 μ M). Co-incubation of DDD85646 at ~2 or 8 × EC50, led to the significant (Significance B, left tailed 
Benjamini-Hochberg FDR, q < 0.05) under-enrichment of 33 and 75 proteins, respectively, in comparison 
with the no drug control (Fig. 7a,b and Table S4). Proteins most sensitive to the inhibition of NMT included 
an ADP-ribosylation factor and homologs of small myristoylated proteins as well as multiple uncharacterised 
proteins. Comparison between the two drug concentrations also revealed a dose-dependent effect of DDD85646 
on the enrichment for 57 proteins supporting our previous findings31. At both concentrations of inhibitor, the 
majority of differentially enriched proteins were annotated with an N-terminal MG (82–84%), inferring their 
myristoylation status (Table S4). Interestingly, the three proteins predicted to be incorrectly annotated (Fig. 6a–c) 
UniProt Accession Protein names First 2 aa
Possible incorrect annotation 
in T. cruzi genomes
Number of genes 
in CL-Brener
Reported N-myristoylation 
in other organisms
Q4D7Y8 ADP-ribosylation factor 1 (ARF1) MG 4 T. brucei61
Q4DPJ1 ADP-ribosylation factor (ARL1) MG 2 T. brucei62
Q4DZM9 ADP-ribosylation factor-like protein MG 1
Q4CV42 Calpain-like cysteine peptidase MG 1 L. major63
Q4CW64 Calpain-like cysteine peptidase MG 1 L. major63
K4E5Y1 Cytoskeleton associated protein CAP5.5 MG 3 T. brucei64
K4DT87 Dynein heavy chain, putative MG 1
K4E5P0 Fatty acyl CoA synthetase 2 MG 2
K4E8Y0 I/6 autoantigen ( microtubule cytoskeleton) MP No, all strains 2
K4E595 Nitrate reductase MG 1
K4EE92 5′ -AMP-activated protein kinase subunit beta, putative KG Yes, Silvio 2 M. musculus13
K4E583 Protein phosphatase 2C MG 1
K4DTB6 Protein phosphatase 2C MG Yes, CL-Brener 1
Q4E4N2 Protein phosphatase 2C MG 1
Q4D0B9 Proteasome regulatory ATPase subunit 2 MG 2 S. cerevisiae14 T. brucei45
Q4CWV8 Iron-sulphur assembly protein 2, putative ML No, all strains 2
K4DXT8 Zinc finger protein MG 2
K4DX27 Uncharacterized protein MS Yes, Silvio 2
K4E0J9 Uncharacterized protein MR ML 1/2 orthologues CL-Brener 2
K4E0P3 Uncharacterized protein MM No, all strains 2
K4E3X3 Uncharacterized protein MY Yes, Silvio 2
Table 1. Selected proteins enriched in at least 2 experiments with predicted function or suspected 
misannotation.  Predicted misannotation was determined by BLAST searching against other T. cruzi 
homologues (see Fig. 6 for alignments). The complete list of 42 proteins with links to orthologues in the  
CL-Brener genome is provided in Table S5.
www.nature.com/scientificreports/
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were significantly less enriched in the presence of the higher concentration of inhibitor, with two out of the three 
under-enriched at the lower concentration also. These data add further evidence that they have been incorrectly 
curated within the T. cruzi genome and are in fact bona-fide N-myristoylated proteins.
Overall, the use of an NMT inhibitor combined with SILAC identifies a higher percentage of substrates with 
greater confidence than that by SILAC based enrichment alone. This is evident by the number of proteins annotated 
with an N-terminal glycine and that DDD85646 inhibits the N-myristoylation of CAP5.5, a known substrate for 
T. cruzi NMT31.
Theoretical versus actual enrichment. Proteins enriched in at least two experimental designs were 
deemed to be consistently enriched with a total of 56 identified after the removal of the duplicate K4E681 
(Fig. S2). Thirty two of these were detected in the three orthogonal experimental approaches. Fifty of these were 
found to have an N-terminal glycine or predicted to have one due to poor curation (Table S5). These consistently 
enriched proteins were compared to their bioinformatics predictions using Myristoylator and both settings of the 
NMT Myr Predictor. However, these programmes were only able to unanimously predict the N-myristoylation 
status for about half of the proteins with an experimentally determined or predicted N-terminal glycine 
(Table S6). Individually, the results were marginally better with Myristoylator, predicting 31 out of 50 proteins 
with a high confidence compared to 26/50 and 21/50 using the all eukaryotes and fungi only settings of the Myr 
Predictor. Comparison of the theoretical masses of the enriched proteins matched the distribution of bands by 
Figure 6. Alignment of non-MG proteins with T. cruzi homologs. Alignments of proteins enriched in SILAC 
and LFQ experiments that appear to have been incorrectly annotated. Proteins are aligned against sequences of 
other strains available in UniProt.
Figure 7. Enrichment of N-myristoylated proteins from DDD856464 treated parasites. Enrichment of 
azidomyristate labelled proteins from epimastigotes also treated with 12.5 μ M (a) and 50 μ M (b) of the NMT 
inhibitor DDD85646. Significantly enriched proteins are shown in red as assessed using significance (b) (FDR 
q < 0.05).
www.nature.com/scientificreports/
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in-gel fluorescence, with the largest number of proteins identified having a mass less than 40 kDa. A large propor-
tion of these enriched proteins have no known function; however from the limited Gene Ontology annotation, it 
is clear that these proteins are involved in a variety of cellular pathways and functions.
As there have recently been reports of the enrichment of N-myristoylated proteins from the malaria parasite 
P. falciparum41 and L. donovani40, we attempted to identify orthologues in the published data from the related 
parasites. As one would expect, we identified more homologs in Leishmania than malaria, although 8 potential 
homologs were identified in both (Table S7). These included two ADP-ribosylation-factor (ARF) family mem-
bers, a proteasome regulatory subunit and several protein phosphatases.
Discussion
With the use of a chemically tractable, metabolic label, we have identified 56 putative N-myristoylated pro-
teins in T. cruzi, of which 32 were detected in the three orthogonal experimental approaches. Forty six 
of the 56 begin with the amino acids MG, with an additional 4 predicted to be MG by alignment with other 
T. cruzi homologues. The enrichment of the latter 4 proteins was reduced by chemical inhibition of NMT by 
the potent and specific inhibitor, DDD85646. Of the remaining 6 proteins, 4 have strong putative mitochon-
drial targeting signals (MitoProt scores 0.86–0.99)with predicted cleavage sites, but none of the amino acids 
following the cleavage sites are glycine. Thus, we can robustly assign 50 proteins as being N-myristoylated in 
T. cruzi, extending our previous report showing that protein myristoylation can be reduced or abolished in 
these parasites in a dose-dependent manner by the potent and specific NMT inhibitor DDD8564631. Studies 
on T. cruzi prior to this investigation have been limited to validating one protein at a time, or to making 
assignments of myristoylation using current bioinformatic prediction software21,42. Despite the limitations 
of the current prediction programs, our study identified 10 homologues (Table S2) previously predicted to 
be enriched in membrane fractions43. The enrichment of FCaBP, identified as myristoylated in the parasite38, 
and of CAP5.5, shown to be a substrate for T. cruzi NMT31, demonstrates the ability to identify N-myristoylated 
proteins from this organism.
Notably, similar enrichments have recently been reported for mammalian cells44, Plasmodium falciparum41 
and the related parasite Leishmania donovani40. In the case of the latter, these authors noted that, although both 
azido and alkynyl myristic acid analogues were incorporated, the alkynyl was superior due to its lower back-
ground labelling and more favourable incorporation40. A comparison was not carried out in T. cruzi due to the 
limitations of the commercial kit used in this study. Nonetheless, we were able to identify the homologs of several 
proteins from the Leishmania N-myristoylome (Table S7). Similarly, we also identified several proteins from an 
enrichment carried out from Plasmodium parasites41 (Table S7). A very recent study on the N-myristoylome of 
T. brucei45 also shows enrichment of about half of the proteins identified here (Table S7) underlining common, as 
well as distinct, elements in the biology of these related parasites.
The downstream analysis of the 56 enriched proteins was complicated by poor annotation and poor curation 
of the proteome. As an example, the three ADP-ribosylation factors (ARF) and ARF-like proteins were anno-
tated with conflicting annotations when compared to the Leishmania ARF proteins (Table S7). Another example 
is the identification of the uncharacterised fragment K4EE92 appears to have a Pfam domain consistent with 
the β -subunit of AMP-activated protein kinase (AMPKβ ), a known myristoylated protein in eukaryotes that is 
involved metabolic stress response and regulation13. T. brucei AMPKβ also possesses a putative N-myristoylation 
signal and is exclusively associated with glycosomes and the flagellum46. The three protein phosphatase 2C 
family members (or metal-dependent protein phosphatases, PPM in more recent terminology) are most sim-
ilar to PPM1A in the mouse genome. Interestingly, these protein phosphatases have been shown to require 
N-myristoylation in order to dephosphorylate the α -subunit of AMPK47, but it is not known if a similar interac-
tion occurs in T. cruzi.
N-myristoylation involves covalent attachment to the N-terminal glycine. The glycine can either be revealed 
during protein synthesis by removal of the initiator methionine residue by methionine amino peptidases 
(co-translational), or during apoptosis where proteolysis by caspases reveals hidden N-myristoylation motifs 
(post-translational)34,44. Although the vast majority of myristoylation appears to be co-translational in our exper-
iments, two of the three most prominent bands appear to be post-translational. However, strong evidence for 
apoptosis or necrosis in these parasites is lacking48 and incidental cell death can be eliminated as a possible cause 
since we found no evidence of loss of cell viability in our experiments. N-myristoylation is generally regarded 
as irreversible, due to the absence of enzymes capable of specifically removing the myristoyl moiety from the 
N-terminal glycine residue. However, there are exceptions. For example, N-myristoylation of the protein kinase 
C MARKS in brain synaptosomes has been reported to occur in the absence of protein synthesis49. Moreover, 
NMT can catalyse the de-myristoylation of a peptide substrate50. This reverse reaction occurs at a rate 1,500 to 
3,000-fold lower50 than N-myristoylation of the peptide. Thus, the failure to completely abolish N-myristoylation 
by complete inhibition of de novo protein synthesis could be explained by the de-acylation of myristic acid and 
re-acylation with azidomyristate-CoA.
In line with the current knowledge in other eukaryotes, it appears that protein myristoylation in T. cruzi is 
involved in a variety of cellular pathways and functions, including: membrane trafficking and cellular transport 
(ARFs and ARLs); cell signalling and regulation of metabolic processes (AMPK and PP2Cs); and cytoskeletal 
remodelling and protein turnover (calpains and the proteasome). However, the majority of proteins are currently 
uncharacterised and have no known functions aside from the identification of a few Pfam domain predictions. It 
therefore appears that there is a large proportion of N-myristoylation biology that has yet to be investigated and 
understood, which may in future provide novel insights into the biology of this parasite.
In summary, this is the most comprehensive enrichment and identification of N-myristoylated proteins 
from this parasite reported to date, as far as we are aware. The genome of the CL-Brener strain is a hybrid of 
Esmeraldo-like and non-Esmeraldo-like haplotypes comprising 23,216 gene models encoding 21,170 proteins, of 
www.nature.com/scientificreports/
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which over 23% of the annotated genes in the genome are members of large gene families, such as trans-sialidases 
and mucins51. Based on the CL-Brener genes listed in Table S5 as probably commencing with MG, we estimate 
0.43% of the proteome is N-myristoylated. A similar value of 0.46% is obtained from the Silvio X10/1 predicted 
proteome (10,876 proteins). These values are marginally lower than the 0.5–1.7% predicted in other eukaryotic 
proteomes20,52,53. This may be a result of only capturing the most abundant N-myristoylated proteins in the par-
asite, which, given the failure to identify two known N-myristoylated proteins, suggests that there may be more 
novel proteins yet to be identified.
Methods
Cell culture. Epimastigotes of the T. cruzi strain Silvio X10/7 clone A (MHOM/BR/78/Silvio; clone X10/7A) 
were grown in RTH medium supplemented with 10% foetal calf serum (FCS, PAA) at 28 °C54. Late-stage cultures 
containing a mixture of epimastigotes and trypomastigotes were used to infect Vero cell monolayers overnight 
with a ratio of 10 parasites per Vero cell. Non-invaded parasites were washed off and after 5–6 days a relatively 
pure population of trypomastigotes was obtained by removing the supernatant. Amastigotes were purified as 
previously described55. Vero cells were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% 
FBS (DMEM/FBS) as described elsewhere56.
Stable Isotope Labelling with Amino Acids in Cell Culture (SILAC). SDM-79 medium depleted 
of both arginine and lysine was reconstituted at the original concentration with either the naturally abundant 
(R0K0), medium labelled (R6K4) or heavy labelled (R10K8) amino acid isotopes (L-arginine.HCl and L-lysine.2HCl, 
CK Gas Products). Dialysed FCS (10% v/v) was used in place of standard FCS and the medium supplemented 
with 100 μ M putrescence before epimastigotes were adapted for growth in the heavy or light media as reported 
for the original SDM-7935.
Visualising N-azidomyristoylated proteins. Parasites were labelled with 50 μ M 12-azidododecanoic 
acid (azidomyristate) for 6 h in either RTH/FCS or DMEM/FCS. Extracts from 5 × 107 cells were made in tryp-
anosome lysis buffer (50 mM Tris-HCl, pH 7.4,150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 1% Triton 
X-100 and a cOmplete mini EDTA-free protease inhibitor cocktail tablet) by incubating on ice for 1 h followed by 
biological inactivation by freeze thawing three times. N-azidomyristoylated proteins from lysates were labelled 
with IRDye 800CW alkyne, using the Click-iT® protein reaction buffer kit (Molecular probes)31. Lysates were 
separated by SDS-PAGE on a 4–12% NUPAGE in MES SDS buffer (Invitrogen), and treated with 1 M NaOH for 
1 h to remove S- and O- myristoylation17. Gels were imaged by in-gel fluorescence with an Odyssey SA infra-
red imager (LI-COR Biosciences). For the inhibition of protein synthesis, parasites were pre-incubated with 
50 μ g ml−1 cycloheximide for 30 min prior to labelling with azidomyristate. Fluorescence intensity profiles were 
extracted using ImageJ (http://imagej.nih.gov/ij/) and plotted as a factor of distance migrated through the gel.
L-[35S]-methionine labelling. Parasites were washed three times in phosphate buffered saline (PBS 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4) and resuspended in methionine-free RTH/
FCS supplemented with or without 50 μ g ml−1 cycloheximide for 30 min prior to the addition of 10 μ Ci ml−1  
L-[35S]-methionine (Perkin Elmer). Lysates were made in Laemmli buffer and separated by SDS-PAGE as 
described above. The gel was treated with En3Hance solution (Perkin Elmer) as per manufacturer’s protocol, 
dried and exposed to BioMax MS film (Kodak) using a TransScreen LE (Kodak).
Live/dead assay. Parasites were washed in PBS and incubated with the live/dead staining mix (5μ g ml−1 
Hoechst 33342 and 2 μ l ml−1 Red Dead Molecular probes) for 15 min at room temperature. Parasites were har-
vested and resuspended in PBS supplemented with 1% formaldehyde. Cells were imaged with an Axiovert 200 
inverted microscope using the appropriate filters, analysing 10 fields of view.
Enrichment of N-azidomyristoylated proteins. Parasites were seeded at a density of 5 × 106 cells ml−1 
and grown in the presence of 50 μ M azidomyristate or DMSO for 20 h (label free) or 12 h (SILAC). Cells were har-
vested by centrifugation (15 min, 1620 × g and 4 °C) and washed twice in PBS to remove the excess label (SILAC 
parasites were mixed in a 1:1 ratio prior to the first wash). N-Azidomyristoylated proteins were enriched using 
the protein enrichment kit (Molecular probes, Life Tech). Parasites (2 × 109) were resuspended in 850 μ l of the 
supplied urea lysis buffer and parasites inactivated by three cycles of freezing and thawing, prior to sonication. 
Soluble protein was obtained after centrifugation (5 min, 10,000 g at 4 °C), and 800 μ l was used for the click chem-
istry immobilisation as per the manufacturers recommendations. Non-specifically interacting proteins were 
removed by washing the resin with the supplied SDS wash buffer followed by equilibration with H2O. The agarose 
was incubated with neutral hydroxylamine to remove S-azidomyristoylated proteins17, and then bound proteins 
were reductively alkylated and further processed according to the suggested protocol.
Mass spectrometry. Agarose immobilised proteins were digested on-resin with trypsin. Protein digestion 
and the subsequent sample processing for analysis by mass spectrometry was carried out by the FingerPrints 
proteomics service (http://proteomics.lifesci.dundee.ac.uk, University of Dundee). Mass spectra were acquired 
on an LTQ Orbitrap Velos Pro as described in the supplementary methods. Thermo Xcalibur raw files were 
processed with MaxQuant57 version 1.5.0.0 which incorporates the Andromeda search engine58. Protein iden-
tifications were made from a custom T. cruzi database comprising the “complete” proteome retrieved from 
UniProt which contains predicted sequences from the CL Brener and Silvio X10/1 strains and T. cruzi marinkellei 
(30,048 entries) in addition to a database of common laboratory contaminants. Searches were carried out using 
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a MS tolerance of 4.5 ppm, an MS/MS tolerance of 0.5 Da and allowing for up to two missed trypsin cleavages. 
Carbamidomethylation of cysteine residues was set as a fixed modification, with the oxidation of methionine and 
N-acetylation were set as variable modifications. Assigned peptides were required to be a minimum of 7 amino 
acid residues in length. Only unique peptides were used to calculate LFQ and SILAC ratios. False discovery rates 
(FDR) were calculated to be < 0.01 by searching a decoy database consisting of reversed sequences. The raw and 
processed mass spectrometry data have been deposited with the ProteomeXchange Consortium (http://www.
proteomexchange.org/)59 using the PRIDE uploader60 under the identifier (PXD002970). Additionally, peptide 
identifications and protein groups have been included in Table S1. Subsequent data processing and analysis was 
performed using Perseus v.1.5.16.
LFQ analysis. Label-free data were processed with the match between runs feature enabled in MaxQuant 
using the settings described above. Data were filtered to remove proteins only identified by site, matching reverse 
sequences and contaminant proteins, prior to transformation to log2 LFQ intensities. The data were filtered to 
require a minimum of 3 valid values prior to the imputation of missing values using a normal distribution (0.1 
width, 1.8 downshift). Statistical significance was assessed using a modified t-test (250 permutations, FDR = 0.05, 
S0 = 2)40.
SILAC enrichment analysis. The data sets were filtered to remove proteins only expressed in one experi-
ment. Raw SILAC H/L ratios were log2-transformed prior to normalisation to the mode ratio in Perseus. Using 
histograms of the label swap experiments, an arbitrary enrichment cut-off of > 1 log2-fold change was assigned 
for each of the normalised datasets.
DDD85646 SILAC enrichment experiment. WT parasites labelled with R0K0, R6K4 or R10K8 were incu-
bated with 50 μ M azidomyristate for 12 h also in the presence of 0, 12.5 and 50 μ M DDD8564630 respectively. An 
equal number of heavy, medium and light labelled parasites were combined and processed as described above for 
the enrichment of N-azidomyristoylated proteins. The dataset is the result of two technical replicates, processed 
in Max Quant using the appropriate labels using both unique and razor peptides for quantification. Using the 
normalized data, significant (FDR q < 0.05) differences in the enrichment of proteins from the experimental 
conditions were assessed in Perseus, using a one tailed Significance B test with a Benjamini-Hochberg FDR trun-
cation implementing a 0.05 threshold value.
Polymyxin acylase digestion. After digestion with trypsin, the agarose was extensively washed with 
20% acetonitrile to remove remaining non-covalently bound peptides and then equilibrated in 50 mM phos-
phate buffer (pH 8.0). Following this, a secondary digestion with 6.4 U of polymyxin acylase (Wako Chemicals) 
was carried out at 37 °C for 24 h37. Peptides were extracted by the FingerPrints proteomics service, University of 
Dundee, desalted and analysed by LC-MS/MS. Data were analysed using a custom programmed enzyme with the 
specificity of trypsin/P with the addition of an enzyme that cleaved between the C-terminus of methionine and 
the N-terminus of glycine.
Bioinformatic searches. Prediction of N-myristoylation was assessed using Myristoylator42 and the NMT 
Myr Predictor21. Comparison of enriched proteins was carried by creating custom BLAST databases in CLC 
workbench using the published results from L. donovani Plasmodium falciparum and T. brucei. BLAST searches 
were carried out using an E-value cut-off of 1 using Blosum62 with a gap cost of existence 11, extension 1.
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